Executive Interview – Carmat

Executive Interview – Carmat

Carmat — 4 videos in collection

Stéphane Piat, CEO of Carmat, discusses the limitations of human heart transplant availability that build the commercial case for the development of its biocompatible artificial heart implant. He also outlines the characteristics that differentiate the Carmat heart from the SynCardia artificial heart and from ventricular assistance devices, which can potentially lead to better tolerability, less thrombosis risk and improved patient outcomes. He then discusses the next steps needed to advance the Carmat heart project and summarises the company’s financial position and requirements.


You may also be interested in these:

Healthcare

Carmat: Edison Open House Healthcare 2022

Healthcare

Carmat - Edison Open House interview

Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.